{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:42:37Z","timestamp":1789123357841,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41030-026-00372-z","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:00:04Z","timestamp":1783519204000},"page":"785-804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sarcoidosis: A Clinical Trials Perspective"],"prefix":"10.1007","volume":"12","author":[{"given":"Juan J.","family":"Zapata-Huizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Herrera-Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josmar J.","family":"R\u00edos-Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli N.","family":"P\u00e9rez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Hern\u00e1ndez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-1670","authenticated-orcid":false,"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"372_CR1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jama.2022.1570","volume":"327","author":"JA Belperio","year":"2022","unstructured":"Belperio JA, Shaikh F, Abtin FG, et al. Diagnosis and treatment of pulmonary sarcoidosis: a review. JAMA. 2022;327:856\u201367.","journal-title":"JAMA"},{"key":"372_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12890-020-01191-x","volume":"20","author":"HS Te","year":"2020","unstructured":"Te HS, Perlman DM, Shenoy C, et al. Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts. BMC Pulm Med. 2020;20:155\u2013155.","journal-title":"BMC Pulm Med"},{"key":"372_CR3","doi-asserted-by":"publisher","first-page":"190146","DOI":"10.1183\/16000617.0146-2019","volume":"29","author":"FF Rahaghi","year":"2020","unstructured":"Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29:190146\u2013190146.","journal-title":"Eur Respir Rev"},{"key":"372_CR4","doi-asserted-by":"publisher","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","volume":"9","author":"ON Obi","year":"2022","unstructured":"Obi ON, Saketkoo LA, Russell A-M, et al. Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches. Front Med. 2022;9:991783\u2013991783.","journal-title":"Front Med"},{"key":"372_CR5","doi-asserted-by":"publisher","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","volume":"58","author":"RP Baughman","year":"2021","unstructured":"Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58:2004079\u20132004079.","journal-title":"Eur Respir J"},{"key":"372_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119\u201324.","journal-title":"Ann Rheum Dis"},{"key":"372_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","volume":"193","author":"J Ramstein","year":"2016","unstructured":"Ramstein J, Broos CE, Simpson LJ, et al. IFN-\u03b3-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type\u00a01 cells. Am J Respir Crit Care Med. 2016;193:1281\u201391.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/thorax-2025-223014","volume":"80","author":"K Bechman","year":"2025","unstructured":"Bechman K, Biddle K, Miracle A, et al. Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis. Thorax. 2025;80:702\u201310.","journal-title":"Thorax"},{"key":"372_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","volume":"174","author":"RP Baughman","year":"2006","unstructured":"Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006;174:795\u2013802.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1183\/09031936.00224513","volume":"43","author":"NJ Sweiss","year":"2014","unstructured":"Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43:1525\u20138.","journal-title":"Eur Respir J"},{"key":"372_CR11","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1183\/09031936.00000914","volume":"44","author":"MA Judson","year":"2014","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44:1296\u2013307.","journal-title":"Eur Respir J"},{"key":"372_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","volume":"199","author":"MA Friedman","year":"2021","unstructured":"Friedman MA, Le B, Stevens J, et al. Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study. Lung. 2021;199:147\u201353.","journal-title":"Lung"},{"key":"372_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","volume":"84","author":"KL Kerkemeyer","year":"2021","unstructured":"Kerkemeyer KL, Meah N, Sinclair RD. Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series. J Am Acad Dermatol. 2021;84:581\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"372_CR14","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","volume":"163","author":"DA Culver","year":"2023","unstructured":"Culver DA, Aryal S, Barney J, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163:881\u201390.","journal-title":"Chest"},{"key":"372_CR15","unstructured":"aTyr Pharma Announces Topline Results from Phase\u00a03 EFZO-FIT\u2122 Study of Efzofitimod in Pulmonary Sarcoidosis | aTyr Pharma. https:\/\/investors.atyrpharma.com\/news-releases\/news-release-details\/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study. Accessed 10 Jan 2026."},{"key":"372_CR16","doi-asserted-by":"publisher","first-page":"2300198","DOI":"10.1183\/13993003.00198-2023","volume":"62","author":"S Dhooria","year":"2023","unstructured":"Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40\u00a0mg) versus low-dose (20\u00a0mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J. 2023;62:2300198\u20132300198.","journal-title":"Eur Respir J"},{"key":"372_CR17","doi-asserted-by":"crossref","unstructured":"Van Den Blink B, Petit C, Dansky HM, et al. RESOLVE-LUNG, a multinational, randomized, placebo-controlled phase\u00a0II trial of namilumab, an anti-GMCSF monoclonal antibody, in chronic pulmonary sarcoidosis: trial design and patient characteristics. European Respiratory Society; 2024. p. OA955\u2013OA955.","DOI":"10.1183\/13993003.congress-2024.OA955"},{"key":"372_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa2501443","volume":"393","author":"V Kahlmann","year":"2025","unstructured":"Kahlmann V, Janssen Bon\u00e1s M, Moor CC, et al. First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate. N Engl J Med. 2025;393:231\u201342.","journal-title":"N Engl J Med"},{"key":"372_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1378\/chest.12-1728","volume":"144","author":"ADM Vorselaars","year":"2013","unstructured":"Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144:805\u201312.","journal-title":"Chest"},{"key":"372_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1183\/09031936.00195010","volume":"38","author":"DH Sahoo","year":"2011","unstructured":"Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38:1145\u201350.","journal-title":"Eur Respir J"},{"key":"372_CR21","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","volume":"108","author":"N Hamzeh","year":"2014","unstructured":"Hamzeh N, Voelker A, Forss\u00e9n A, et al. Efficacy of mycophenolate mofetil in sarcoidosis. Respir Med. 2014;108:1663\u20139.","journal-title":"Respir Med"},{"key":"372_CR22","first-page":"46","volume":"31","author":"NJ Sweiss","year":"2014","unstructured":"Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:46\u201354.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR23","first-page":"100004","volume":"1","author":"M Sharp","year":"2019","unstructured":"Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004\u2013100004.","journal-title":"Respir Med X"},{"key":"372_CR24","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/rheumatology\/kead373","volume":"63","author":"MC Baker","year":"2024","unstructured":"Baker MC, Horomanski A, Wang Y, et al. A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis. Rheumatology. 2024;63:1297\u2013304.","journal-title":"Rheumatology"},{"key":"372_CR25","doi-asserted-by":"publisher","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","volume":"52","author":"C Rotenberg","year":"2018","unstructured":"Rotenberg C, Besnard V, Brillet P-Y, et al. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018;52:1801482\u20131801482.","journal-title":"Eur Respir J"},{"key":"372_CR26","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","volume":"6","author":"A Redl","year":"2024","unstructured":"Redl A, Doberer K, Unterluggauer L, et al. Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial. Lancet Rheumatol. 2024;6:e81\u201391.","journal-title":"Lancet Rheumatol"},{"key":"372_CR27","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"372_CR28","first-page":"e2022011","volume":"39","author":"RP Baughman","year":"2022","unstructured":"Baughman RP, Gupta R, Judson MA, et al. Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39:e2022011\u2013e2022011.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00338-8","author":"AU Wells","year":"2025","unstructured":"Wells AU, Lower EE, Baughman RP, et al. A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders. Lancet Respir Med. 2025. https:\/\/doi.org\/10.1016\/S2213-2600(25)00338-8.","journal-title":"Lancet Respir Med"},{"key":"372_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd001114.pub2","author":"NS Paramothayan","year":"2005","unstructured":"Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005. https:\/\/doi.org\/10.1002\/14651858.cd001114.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"372_CR31","doi-asserted-by":"publisher","first-page":"l5553","DOI":"10.1136\/bmj.l5553","volume":"367","author":"DA Culver","year":"2019","unstructured":"Culver DA, Judson MA. New advances in the management of pulmonary sarcoidosis. BMJ. 2019;367:l5553\u2013l5553.","journal-title":"BMJ"},{"key":"372_CR32","doi-asserted-by":"crossref","unstructured":"Costabel U, Hunninghake GW. ATS\/ERS\/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J. 1999;14:735\u20137.","DOI":"10.1034\/j.1399-3003.1999.14d02.x"},{"key":"372_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","volume":"76","author":"M Thillai","year":"2021","unstructured":"Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76:4\u201320.","journal-title":"Thorax"},{"key":"372_CR34","doi-asserted-by":"publisher","first-page":"2301629","DOI":"10.1183\/13993003.01629-2023","volume":"63","author":"F Jeny","year":"2024","unstructured":"Jeny F, Nunes H, Valeyre D. In sarcoidosis trials, time also matters. Eur Respir J. 2024;63:2301629\u20132301629.","journal-title":"Eur Respir J"},{"key":"372_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","volume":"88","author":"Y Yazaki","year":"2001","unstructured":"Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006\u201310.","journal-title":"Am J Cardiol"},{"key":"372_CR36","first-page":"1034","volume":"29","author":"MM Sadek","year":"2013","unstructured":"Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034\u201341.","journal-title":"Can J Cardiol"},{"key":"372_CR37","doi-asserted-by":"publisher","first-page":"e1003432","DOI":"10.1371\/journal.pmed.1003432","volume":"17","author":"M Pujades-Rodriguez","year":"2020","unstructured":"Pujades-Rodriguez M, Morgan AW, Cubbon RM, et al. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLOS Med. 2020;17:e1003432\u2013e1003432.","journal-title":"PLOS Med"},{"key":"372_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejim.2022.12.003","volume":"109","author":"M Rezaee","year":"2023","unstructured":"Rezaee M, Zangiabadian M, Soheili A, et al. Role of anti-tumor necrosis factor-alpha agents in treatment of sarcoidosis: a meta-analysis. Eur J Intern Med. 2023;109:42\u20139.","journal-title":"Eur J Intern Med"},{"key":"372_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12931-024-02758-6","volume":"25","author":"E Rivi\u00e8re","year":"2024","unstructured":"Rivi\u00e8re E, Jourde W, Gensous N, et al. Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients. Respir Res. 2024;25:124\u2013124.","journal-title":"Respir Res"},{"key":"372_CR40","first-page":"201","volume":"23","author":"MD Rossman","year":"2006","unstructured":"Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2006;23:201\u20138.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR41","first-page":"17859","volume":"42","author":"RP Baughman","year":"2025","unstructured":"Baughman RP, Lower EE, Culver DA, et al. WASOG clinical trial endpoint task force: executive summary. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42:17859\u201317859.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","volume":"19","author":"JP Cremers","year":"2013","unstructured":"Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med. 2013;19:545\u201361.","journal-title":"Curr Opin Pulm Med"},{"key":"372_CR43","first-page":"217","volume":"36","author":"C Fang","year":"2019","unstructured":"Fang C, Zhang Q, Wang N, et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36:217\u201327.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR44","first-page":"e2020001","volume":"37","author":"RP Baughman","year":"2020","unstructured":"Baughman RP, Cremers JP, Harmon M, et al. Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37:e2020001\u2013e2020001.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR45","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMe2504736","volume":"393","author":"RP Baughman","year":"2025","unstructured":"Baughman RP, Lower EE. Methotrexate as initial therapy for symptomatic pulmonary sarcoidosis? N Engl J Med. 2025;393:303\u20135.","journal-title":"N Engl J Med"},{"key":"372_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","volume":"3","author":"RP Baughman","year":"2015","unstructured":"Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;3:813\u201322.","journal-title":"Lancet Respir Med"},{"key":"372_CR47","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keae692","volume":"64","author":"L Brooks","year":"2025","unstructured":"Brooks L, Kivlin W, Mohananey D, et al. Comparative effectiveness of disease-modifying antirheumatic drugs for patients with cardiac sarcoidosis. Rheumatology. 2025;64:3303\u20138.","journal-title":"Rheumatology"},{"key":"372_CR48","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/17512433.2018.1486706","volume":"11","author":"WE James","year":"2018","unstructured":"James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11:677\u201387.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"372_CR49","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1183\/09031936.00051907","volume":"31","author":"MA Judson","year":"2008","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J. 2008;31:1189\u201396.","journal-title":"Eur Respir J"},{"key":"372_CR50","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1752-699X.2011.00276.x","volume":"6","author":"N Milman","year":"2012","unstructured":"Milman N, Graudal N, Loft A, et al. Effect of the TNF-\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET. Clin Respir J. 2012;6:238\u201347.","journal-title":"Clin Respir J"},{"key":"372_CR51","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent. N Engl J Med. 2001;345:1098\u2013104.","journal-title":"N Engl J Med"},{"key":"372_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64:625\u201339.","journal-title":"Arthritis Care Res"},{"key":"372_CR53","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","volume":"86","author":"MJ Murphy","year":"2022","unstructured":"Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis. J Am Acad Dermatol. 2022;86:1080\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"372_CR54","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-025-00338-7","author":"JJR Poveda","year":"2026","unstructured":"Poveda JJR, Tamayo MH, Huizi JJZ, et al. Drug-induced pulmonary toxicity in the era of immunotherapy and biologics: a narrative review of mechanism, diagnosis, and management. Pulm Ther. 2026. https:\/\/doi.org\/10.1007\/s41030-025-00338-7.","journal-title":"Pulm Ther"},{"key":"372_CR55","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1183\/09031936.00156314","volume":"44","author":"DR Moller","year":"2014","unstructured":"Moller DR. Negative clinical trials in sarcoidosis: failed therapies or flawed study design? Eur Respir J. 2014;44:1123\u20136.","journal-title":"Eur Respir J"},{"key":"372_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2013.11.019","volume":"108","author":"MA Judson","year":"2014","unstructured":"Judson MA, Baughman RP, Costabel U, et al. The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial. Respir Med. 2014;108:189\u201394.","journal-title":"Respir Med"},{"key":"372_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12948-015-0025-9","volume":"13","author":"F Cinetto","year":"2015","unstructured":"Cinetto F, Compagno N, Scarpa R, et al. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13:19\u201319.","journal-title":"Clin Mol Allergy"},{"key":"372_CR58","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00415-025-13209-7","volume":"272","author":"SK Hutto","year":"2025","unstructured":"Hutto SK, Balaban D, Rohm Z, et al. Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study. J Neurol. 2025;272:519\u2013519.","journal-title":"J Neurol"},{"key":"372_CR59","first-page":"e2023011","volume":"40","author":"RP Baughman","year":"2023","unstructured":"Baughman RP, Niranjan V, Walker G, et al. Efzofitimod: a novel anti-inflammatory agent for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023;40:e2023011\u2013e2023011.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR60","doi-asserted-by":"publisher","first-page":"eadp4754","DOI":"10.1126\/scitranslmed.adp4754","volume":"17","author":"LA Nangle","year":"2025","unstructured":"Nangle LA, Xu Z, Siefker D, et al. A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis. Sci Transl Med. 2025;17:eadp4754\u2013eadp4754.","journal-title":"Sci Transl Med"},{"key":"372_CR61","doi-asserted-by":"publisher","first-page":"00536","DOI":"10.1183\/23120541.00536-2024","volume":"11","author":"ON Obi","year":"2025","unstructured":"Obi ON, Baughman RP, Crouser ED, et al. Therapeutic doses of efzofitimod demonstrate efficacy in pulmonary sarcoidosis. ERJ Open Res. 2025;11:00536\u20132024.","journal-title":"ERJ Open Res"},{"key":"372_CR62","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1440-1843.1998.tb00130.x","volume":"3","author":"A Itoh","year":"1998","unstructured":"Itoh A, Yamaguchi E, Furuya K, et al. Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis. Respirol Carlton Vic. 1998;3:247\u201351.","journal-title":"Respirol Carlton Vic"},{"key":"372_CR63","first-page":"139","volume":"13","author":"S Ishioka","year":"1996","unstructured":"Ishioka S, Saito T, Hiyama K, et al. Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13:139\u201345.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"372_CR64","first-page":"242","volume":"102","author":"I Terao","year":"1993","unstructured":"Terao I, Hashimoto S, Horie T. Effect of GM-CSF on TNF-alpha and IL-1-beta production by alveolar macrophages and peripheral blood monocytes from patients with sarcoidosis. Int Arch Allergy Immunol. 1993;102:242\u20138.","journal-title":"Int Arch Allergy Immunol"},{"key":"372_CR65","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1136\/thx.48.12.1230","volume":"48","author":"A Itoh","year":"1993","unstructured":"Itoh A, Yamaguchi E, Furuya K, et al. Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis. Thorax. 1993;48:1230\u20134.","journal-title":"Thorax"},{"key":"372_CR66","unstructured":"Roivant Announces Topline Results from Phase\u00a02 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis | Roivant Sciences Ltd. https:\/\/investor.roivant.com\/news-releases\/news-release-details\/roivant-announces-topline-results-phase-2-resolve-lung-study\/. Accessed 10 Jan 2026."},{"key":"372_CR67","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1164\/ajrccm.152.1.7599865","volume":"152","author":"RE Girgis","year":"1995","unstructured":"Girgis RE, Basha MA, Maliarik M, et al. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med. 1995;152:71\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103247","author":"J Miedema","year":"2024","unstructured":"Miedema J, Cinetto F, Smed-S\u00f6rensen A, et al. The immunopathogenesis of sarcoidosis. J Autoimmun. 2024. https:\/\/doi.org\/10.1016\/j.jaut.2024.103247.","journal-title":"J Autoimmun"},{"key":"372_CR69","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","volume":"379","author":"W Damsky","year":"2018","unstructured":"Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379:2540\u20136.","journal-title":"N Engl J Med"},{"key":"372_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ni.3655","volume":"18","author":"M Linke","year":"2017","unstructured":"Linke M, Pham HTT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18:293\u2013302.","journal-title":"Nat Immunol"},{"key":"372_CR71","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1164\/rccm.200905-0696OC","volume":"181","author":"ES Chen","year":"2010","unstructured":"Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181:360\u201373.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR72","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrrheum.2011.93","volume":"7","author":"ES Chen","year":"2011","unstructured":"Chen ES, Moller DR. Sarcoidosis\u2013scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7:457\u201367.","journal-title":"Nat Rev Rheumatol"},{"key":"372_CR73","unstructured":"Study Details | NCT02888080 | Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT02888080. Accessed 11 Jan 2026."},{"key":"372_CR74","unstructured":"Study Details | NCT04064242 | Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis | ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT04064242. Accessed 11 Jan 2026."},{"key":"372_CR75","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","volume":"82","author":"W Damsky","year":"2020","unstructured":"Damsky W, Thakral D, McGeary MK, et al. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82:612\u201321.","journal-title":"J Am Acad Dermatol"},{"key":"372_CR76","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","volume":"7","author":"T Zhou","year":"2017","unstructured":"Zhou T, Casanova N, Pouladi N, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7:4237\u20134237.","journal-title":"Sci Rep"},{"key":"372_CR77","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","volume":"13","author":"W Damsky","year":"2022","unstructured":"Damsky W, Wang A, Kim DJ, et al. Inhibition of type\u00a01 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022;13:3140\u20133140.","journal-title":"Nat Commun"},{"key":"372_CR78","first-page":"2167","volume":"42","author":"HCB Leffers","year":"2024","unstructured":"Leffers HCB, Baslund B, Lindhardsen J, et al. Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response. Clin Exp Rheumatol. 2024;42:2167\u201374.","journal-title":"Clin Exp Rheumatol"},{"key":"372_CR79","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1164\/rccm.202004-0914IM","volume":"202","author":"N Gupta","year":"2020","unstructured":"Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202:e119\u201320.","journal-title":"Am J Respir Crit Care Med"},{"key":"372_CR80","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.pulmoe.2024.03.002","volume":"30","author":"R Hindr\u00e9","year":"2024","unstructured":"Hindr\u00e9 R, Besnard V, Kort F, et al. Complete response to mTOR inhibitor following JAKi failure in severe pulmonary sarcoidosis. Pulmonology. 2024;30:639\u201341.","journal-title":"Pulmonology"},{"key":"372_CR81","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","volume":"19","author":"M Ghazipura","year":"2022","unstructured":"Ghazipura M, Mammen MJ, Herman DD, et al. Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19:1040\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"372_CR82","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360.","journal-title":"Lancet Respir Med"},{"key":"372_CR83","doi-asserted-by":"publisher","first-page":"240259","DOI":"10.1183\/20734735.0259-2024","volume":"21","author":"A Denis","year":"2025","unstructured":"Denis A, Tsiri P, Guiot J, et al. A new era in the treatment of progressive fibrosing interstitial lung diseases. Breathe. 2025;21:240259\u2013240259.","journal-title":"Breathe"},{"key":"372_CR84","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.rmed.2017.11.010","volume":"138","author":"MA Judson","year":"2018","unstructured":"Judson MA. Endpoints in sarcoidosis: more like IPF or asthma? Respir Med. 2018;138:S3\u20134.","journal-title":"Respir Med"},{"key":"372_CR85","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/MCP.0000000000000193","volume":"21","author":"RP Baughman","year":"2015","unstructured":"Baughman RP, Lower EE, Saketkoo LA. Clinical trials in pulmonary sarcoidosis. Curr Opin Pulm Med. 2015;21:525\u201331.","journal-title":"Curr Opin Pulm Med"},{"key":"372_CR86","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1055\/a-2741-2030","volume":"46","author":"MB Pascual","year":"2025","unstructured":"Pascual MB, Zapata-Huizi JJ, Ramos D, et al. Biomarkers in sarcoidosis: from traditional markers to precision medicine. Semin Respir Crit Care Med. 2025;46:594\u2013601.","journal-title":"Semin Respir Crit Care Med"},{"key":"372_CR87","doi-asserted-by":"publisher","first-page":"2500943","DOI":"10.1183\/13993003.00943-2025","volume":"66","author":"RP Baughman","year":"2025","unstructured":"Baughman RP, Grutters JC, Lower EE, et al. Pulmonary sarcoidosis clinical trial end-points: a Delphi study. Eur Respir J. 2025;66:2500943.","journal-title":"Eur Respir J"},{"key":"372_CR88","doi-asserted-by":"publisher","first-page":"100137","DOI":"10.1016\/j.opresp.2021.100137","volume":"3","author":"J Francesqui","year":"2021","unstructured":"Francesqui J, Hern\u00e1ndez-Gonz\u00e1lez F, Sellar\u00e9s J. Sarcoidosis phenotypes. Open Respir Arch. 2021;3:100137\u2013100137.","journal-title":"Open Respir Arch"},{"key":"372_CR89","doi-asserted-by":"publisher","first-page":"190145","DOI":"10.1183\/16000617.0145-2019","volume":"29","author":"RP Baughman","year":"2020","unstructured":"Baughman RP, Scholand MB, Rahaghi FF. Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev. 2020;29:190145\u2013190145.","journal-title":"Eur Respir Rev"},{"key":"372_CR90","unstructured":"Study Details | NCT06205121 | Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis | ClinicalTrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT06205121. Accessed 12 Jan 2026."},{"key":"372_CR91","unstructured":"Assistance Publique\u2014H\u00f4pitaux de Paris. Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis. Clinical Trial Registration NCT05247554, clinicaltrials.gov, https:\/\/clinicaltrials.gov\/study\/NCT05247554 (9 Feb 2022). Accessed 16 Apr 2026."},{"key":"372_CR92","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/postgradmedj-2014-132584","volume":"90","author":"S Dubrey","year":"2014","unstructured":"Dubrey S, Shah S, Hardman T, et al. Sarcoidosis: the links between epidemiology and aetiology. Postgrad Med J. 2014;90:582\u20139.","journal-title":"Postgrad Med J"},{"key":"372_CR93","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12016-015-8481-z","volume":"49","author":"ES Chen","year":"2015","unstructured":"Chen ES, Moller DR. Etiologies of sarcoidosis. Clin Rev Allergy Immunol. 2015;49:6\u201318.","journal-title":"Clin Rev Allergy Immunol"},{"key":"372_CR94","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","volume":"14","author":"DR Moller","year":"2017","unstructured":"Moller DR, Rybicki BA, Hamzeh NY, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc. 2017;14:S429\u201336.","journal-title":"Ann Am Thorac Soc"},{"key":"372_CR95","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11882-025-01222-9","volume":"25","author":"NV Rivera","year":"2025","unstructured":"Rivera NV, Isra\u00ebl-Biet D. Sarcoidosis in the genomic era: from genetic drivers to tailored therapies. Curr Allergy Asthma Rep. 2025;25:42\u201342.","journal-title":"Curr Allergy Asthma Rep"},{"key":"372_CR96","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1055\/s-0037-1602380","volume":"38","author":"B Karakaya","year":"2017","unstructured":"Karakaya B, Kaiser Y, van Moorsel CHM, et al. L\u00f6fgren\u2019s syndrome: diagnosis, management, and disease pathogenesis. Semin Respir Crit Care Med. 2017;38:463\u201376.","journal-title":"Semin Respir Crit Care Med"},{"key":"372_CR97","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s42399-025-01845-z","volume":"7","author":"AL Peralta-Amaro","year":"2025","unstructured":"Peralta-Amaro AL, Linares-Liberato G, L\u00f3pez-Flores AM, et al. Progressive chronic sarcoidosis: a report of multiorgan involvement in a young woman and a literature review. SN Compr Clin Med. 2025;7:94\u201394.","journal-title":"SN Compr Clin Med"},{"key":"372_CR98","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","volume":"149","author":"RK Cheng","year":"2024","unstructured":"Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation. 2024;149:e1197\u2013216.","journal-title":"Circulation"},{"key":"372_CR99","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2017.12.012","volume":"87","author":"JR Miedema","year":"2018","unstructured":"Miedema JR, Kaiser Y, Broos CE, et al. Th17-lineage cells in pulmonary sarcoidosis and L\u00f6fgren\u2019s syndrome: friend or foe? J Autoimmun. 2018;87:82\u201396.","journal-title":"J Autoimmun"},{"key":"372_CR100","doi-asserted-by":"publisher","first-page":"1301991","DOI":"10.3389\/fimmu.2023.1301991","volume":"14","author":"KC Patterson","year":"2023","unstructured":"Patterson KC, Miller WT, Hancock WW, et al. FOXP3+ regulatory T\u00a0cells are associated with the severity and prognosis of sarcoidosis. Front Immunol. 2023;14:1301991\u20131301991.","journal-title":"Front Immunol"},{"key":"372_CR101","doi-asserted-by":"publisher","first-page":"L480","DOI":"10.1152\/ajplung.00082.2024","volume":"326","author":"CA Bonham","year":"2024","unstructured":"Bonham CA, Sharp M. New updates in sarcoidosis research: defining and renewing the quest. Am J Physiol Lung Cell Mol Physiol. 2024;326:L480\u20131.","journal-title":"Am J Physiol Lung Cell Mol Physiol"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00372-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-026-00372-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-026-00372-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:02:29Z","timestamp":1789120949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-026-00372-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1007\/s41030-026-00372-z","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fernanda Hern\u00e1ndez-Gonz\u00e1lez and Jacobo Sellares report honoraria for lectures, educational events, and support for attending meetings from Roche, Boehringer Ingelheim, AztraZeneca, Gebro, and GSK, outside the submitted work. Jacobo Sellares discloses consulting fees from Boehringer Ingelheim and Alofarma, and grants from Roche and Boehringer Ingelheim, all outside the submitted work. Jacobo Sellares is an Editorial Board member of\n                      Pulmonary Therapy\n                      . Jacobo Sellares was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Juan Jos\u00e9 Zapata-Huizi, Manuela Herrera-Tamayo, Josmar Jesvi R\u00edos-Poveda, and Eli Nancy P\u00e9rez-Rodas have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This narrative review is based on previously published studies and does not include any new studies with human participants or animals performed by the authors. The studies and clinical trials cited herein have their own ethical review and approval procedures detailed in their respective protocols. In accordance with Hospital Cl\u00ednic de Barcelona policies, this activity does not constitute human-subjects research, and institutional review board\/ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}